Lethal myocardial reperfusion injury: A necessary evil?

被引:28
作者
Ibanez, Borja [1 ,2 ]
Fuster, Valentin [1 ,3 ]
Jimenez-Borreguero, Jesus [1 ]
Badimon, Juan J. [3 ]
机构
[1] Fdn Ctr Nacl Invest Cardiovasc Carlos III CNIC, Madrid, Spain
[2] Univ Complutense Madrid, Hosp Clin San Carlos, Madrid, Spain
[3] Mt Sinai Sch Med, Atherothrombosis Res Unit, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA
关键词
Cardioprotection; Ischemia-reperfusion; Beta-blockers; Adrenergic receptors; Myocardial salvage; Myocardial infarction; Reperfusion injury; MITOCHONDRIAL PERMEABILITY TRANSITION; PERCUTANEOUS CORONARY INTERVENTION; GLUCAGON-LIKE PEPTIDE-1; ATRIAL-NATRIURETIC-PEPTIDE; INTRAVENOUS BETA-BLOCKADE; INSULIN-POTASSIUM THERAPY; ACTIVATED PROTEIN-KINASE; INFARCT SIZE-REDUCTION; ISCHEMIA-REPERFUSION; CELL-DEATH;
D O I
10.1016/j.ijcard.2010.10.056
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite being the most effective means of limiting infarct size, coronary reperfusion comes at a price and induces additional damage to the myocardium. Lethal reperfusion injury (death of myocytes that were viable at the time of reperfusion) is an increasingly acknowledged phenomenon. There are many interconnected mechanisms involved in this type of cell death. Calcium overload (generating myocyte hypercontracture), rapid recovery of physiological pH, neutrophil infiltration of the ischemic area, opening of the mitochondrial permeability-transition-pore (PTP), and apoptotic cell death are among the more important mechanisms involved in reperfusion injury. The activation of a group of proteins called reperfusion injury salvage kinases (RISK) pathway confers protection against reperfusion injury, mainly by inhibiting the opening of the mitochondrial PTP. Many interventions have been tested in human trials triggered by encouraging animal studies. In the present review we will explain in detail the main mechanism involved in reperfusion injury, as well as the various approaches (pre-clinical and human trials) performed targeting these mechanisms. Currently, no intervention has been consistently shown to reduce reperfusion injury in large randomized multicenter trials, but the research in this field is intense and the future is highly promising. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:3 / 11
页数:9
相关论文
共 140 条
[1]   2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction - A report of the American college of cardiology/American heart association task force on practice guidelines [J].
Antman, Elliott M. ;
Hand, Mary ;
Armstrong, Paul W. ;
Bates, Eric R. ;
Green, Lee A. ;
Halasyamani, Lakshmi K. ;
Hochman, Judith S. ;
Krumholz, Harlan M. ;
Lamas, Gervasio A. ;
Mullany, Charles J. ;
Pearle, David L. ;
Sloan, Michael A. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2008, 117 (02) :296-329
[2]   A challenge to the metabolic approach to myocardial ischaemia [J].
Apstein, CS ;
Opie, LH .
EUROPEAN HEART JOURNAL, 2005, 26 (10) :956-959
[3]   Postconditioning inhibits mitochondrial permeability transition [J].
Argaud, L ;
Gateau-Roesch, O ;
Raisky, O ;
Loufouat, J ;
Robert, D ;
Ovize, M .
CIRCULATION, 2005, 111 (02) :194-197
[4]   Preconditioning delays Ca2+-induced mitochondrial permeability transition [J].
Argaud, L ;
Gateau-Roesch, O ;
Chalabreysse, L ;
Gomez, L ;
Loufouat, J ;
Thivolet-Béjui, F ;
Robert, D ;
Ovize, M .
CARDIOVASCULAR RESEARCH, 2004, 61 (01) :115-122
[5]  
Armstrong PW, 2007, JAMA-J AM MED ASSOC, V297, P43
[6]   Effect of Intravenous FX06 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction Results of the FIRE (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) Trial [J].
Atar, Dan ;
Petzelbauer, Peter ;
Schwitter, Jurg ;
Huber, Kurt ;
Rensing, Benno ;
Kasprzak, Jaroslaw D. ;
Butter, Christian ;
Grip, Lars ;
Hansen, Peter R. ;
Suselbeck, Tim ;
Clemmensen, Peter M. ;
Marin-Galiano, Marcos ;
Geudelin, Bernard ;
Buser, Peter T. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (08) :720-729
[7]   Na+/H+ exchange inhibitors for cardioprotective therapy:: Progress, problems and prospects [J].
Avkiran, M ;
Marber, MS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) :747-753
[8]   Results of the first clinical study of adjunctive caldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction:: the randomized multicentre CASTEMI study [J].
Bar, Frits W. ;
Tzivoni, Dan ;
Dirksen, Maurits T. ;
Fernandez-Ortiz, Antonio ;
Heyndrickx, Guy R. ;
Brachmann, Johannes ;
Reiber, Johan H. C. ;
Avasthy, Neelima ;
Tatsuno, Jun ;
Davies, Martin ;
Hibberd, Mark G. ;
Krucoff, Mitchell W. .
EUROPEAN HEART JOURNAL, 2006, 27 (21) :2516-2523
[9]   Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway [J].
Bell, RM ;
Yellon, DM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (03) :508-515
[10]   The myocardial JAK/STAT pathway: From protection to failure [J].
Boengler, Kerstin ;
Hilfiker-Kleiner, Denise ;
Drexler, Helmut ;
Heusch, Gerd ;
Schulz, Rainer .
PHARMACOLOGY & THERAPEUTICS, 2008, 120 (02) :172-185